X

Drug Profile

Talipexole

Alternative Names: BHT 920; Domin

Latest Information Update: 31 May 2006

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Boehringer Ingelheim Pharma KG
Class Antiparkinsonians; Azepines
Mechanism of Action Alpha 2 adrenergic receptor agonists; Dopamine D2 receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Marketed Parkinson's disease
Discontinued Psychotic disorders

Most Recent Events

31 May 2006 No development reported - Phase-II for Parkinson's disease in USA (PO)
31 May 2006 No development reported - Phase-III for Parkinson's disease in Germany (PO)
31 May 2006 No development reported - Preclinical for Parkinson's disease in Netherlands (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com